May. 10 at 1:26 PM
$CURLF feels set up well into this week. Q1 was exactly what this sector needed:
$324M revenue, 6% YoY growth, 49% gross margin, ~
$63M adjusted EBITDA, and positive FCF. That is not a broken OTC story. That is a real operator generating over 1 billion in revenue and growing waiting on a broken federal framework to finally catch up.
Rescheduling hearing starts June 29, and the setup keeps improving. If 280E relief, banking, uplist potential, and institutional access start lining up, Curaleaf is one of the names positioned to benefit pretty much more than any other weed company.